Naratriptan

ناراتریپتان

⚠ Unverified

🧠 Nervous SystemTriptan (5-HT1B/1D agonist)

Market / country: 🇺🇸 USA

Amerge (US)

🧮 Dose calculator

Acute migraine attack · Regimen source: FDA Naratriptan · 2.1

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

  • ⛔ Ischaemic coronary disease or coronary vasospasm (Prinzmetal); WPW or accessory-pathway arrhythmias; history of stroke, TIA or hemiplegic/basilar migraine; peripheral vascular disease; ischaemic bowel disease; uncontrolled hypertension; another triptan or ergot within 24 h; hypersensitivity. FDA Naratriptan · 4
  • ⛔ Severe renal impairment (CrCl <15) or severe hepatic impairment (Child-Pugh C). FDA Naratriptan · 2.2FDA Naratriptan · 2.3

Warnings

  • • Myocardial ischaemia and infarction; arrhythmias; chest/throat/jaw tightness; cerebrovascular events; medication-overuse headache; serotonin syndrome; increased blood pressure. FDA Naratriptan · 5

Renal adjustment

Formulations

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Naratriptan · 8.1

    “Risk Summary There are no adequate data on the developmental risk associated with use of naratriptan tablets in pregnant women.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Naratriptan · 8.2

    “Risk Summary There are no data on the presence of naratriptan in human milk, the effects of naratriptan on the breastfed infant, or the effects of naratriptan on milk production.”
  • 👶 ChildrenSafety not established

    Label: safety and effectiveness in children have not been established. FDA Naratriptan · 8.4

    “Safety and effectiveness in pediatric patients have not been established.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Naratriptan · 8.5

    “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav